Sumitomo Pharma revenue and financials

4506 · TSE · JPY

Compare Sumitomo Pharma
¥2,018.00Change from previous close: −0.49%Absolute change: −¥10.00

Close · November 16, 2026

In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.

Annual revenue · 2026: ¥453.29B
  1. ¥411.64B2017
  2. ¥466.84B2018
  3. ¥459.27B2019
  4. ¥482.73B2020
  5. ¥515.95B2021
  6. ¥560.04B2022
  7. ¥555.54B2023
  8. ¥314.56B2024
  9. ¥398.83B2025
  10. ¥453.29B2026

Fiscal year ending in March. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+13.66%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+352.17%
FY to Mar 2026 vs FY to Mar 2025
Net margin
23.6%
FY to Mar 2025: 5.9%

How Sumitomo Pharma is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of JPY; per-share values in JPY; shares in millions.

Income statement · Annual
ItemFY to Mar 2026FY to Mar 2025FY to Mar 2024FY to Mar 2023FY to Mar 2022FY to Mar 2021FY to Mar 2020FY to Mar 2019FY to Mar 2018FY to Mar 2017
Total revenue453,294398,832314,558555,544560,035515,952482,732459,267466,838411,638
Cost of revenue196,401153,330126,577178,919157,127137,773129,673113,553112,345100,071
Gross profit256,893245,502187,981376,625402,908378,179353,059345,714354,493311,567
Selling, general and administrative163,016180,155397,705339,212217,339173,666143,076172,581177,113172,335
Research and development43,99649,865112,637131,85894,903132,682115,112102,36486,92880,819
Operating income52,80117,770-355,136-126,34959,96754,29982,92261,27282,71852,759
EBIT52,80117,770-355,136-126,34959,96754,29982,92261,27282,71852,759
EBITDA71,92941,044-317,371-85,08698,31576,972100,28775,24895,60571,376
Interest expense5,3654,5803,8932,6402,9702,436699178394631
Pre-tax income100,34417,611-323,114-47,92082,96177,85183,94765,04684,86647,217
Income tax-6,521-6,024-8,18548,79442,36141,02248,02916,41931,41818,226
Net income106,86523,634-314,969-74,51256,41356,21940,75348,62753,44828,991
Net income to common shareholders106,86523,634-314,969-74,51256,41356,21940,75348,62753,44828,991
Basic EPS268.9959.49-792.79-187.55141.99141.50102.58122.39134.5372.97
Diluted EPS268.9959.49-792.79-187.55141.99141.50102.58122.39134.5372.97
Average shares (basic)397397397397397397397397397397
Average shares (diluted)397397397397397397397397397397
Dividend per share———21.0028.0028.0028.0026.0018.0018.00

Companies in the group: same industry, similar size